<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03714646</url>
  </required_header>
  <id_info>
    <org_study_id>NL63759.068.17</org_study_id>
    <nct_id>NCT03714646</nct_id>
  </id_info>
  <brief_title>Beta Glucan and Acetate Production</brief_title>
  <official_title>The Effects of Beta Glucan on Acetate Production and Human Substrate Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on our hypothesis that orally administered resistant starch and beta glucan will be
      fermented into a SCFA pattern high in acetate and that this will lead to beneficial effects
      on human substrate and energy metabolism, we aim to address the following primary objective:

      To investigate the effects of an acute administration of inulin/beta glucan in combination
      with resistant starch on fecal and plasma acetate, as well as on fasting and postprandial
      substrate and energy metabolism in lean normoglycemic men and obese, prediabetic men.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma acetate concentrations (microM)</measure>
    <time_frame>at baseline (before a high-fat mixed meal)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma acetate concentrations (microM)</measure>
    <time_frame>four hours after a high fat mixed meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy expenditure (kJ/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fat oxidation (g/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carbohydrate oxidation (g/min) will be measured using an open-circuit ventilated hood system (Omnical, Maastricht University, The Netherlands)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating hormone concentrations (Insulin, GLP-1, PYY)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating metabolite concentrations (Glucose, Free Fatty Acids, Triglycerides)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose (mmol/L)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Fatty Acids (micromol/L)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath H2 using (Bedfont EC60 Gastrolyzer, Rochester, UK)</measure>
    <time_frame>at baseline and four hours after a high fat mixed meal</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Pre Diabetes</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>beta glucan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>beta glucan and Resistant Starch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>beta glucan and resistant starch</intervention_name>
    <description>12g per day the day before the CID Resistant starch 7.5 g</description>
    <arm_group_label>beta glucan and Resistant Starch</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>isocaloric maltodextrin before the CID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>beta gluten</intervention_name>
    <description>12 g beta gluten there day before the CID</description>
    <arm_group_label>beta glucan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  lean (BMI ≥ 20kg/m2 and ≤ 24.9kg/m2)

          -  normoglycemic

          -  aged 30 - 65 years

        OR

          -  overweight/obese (BMI ≥ 25kg/m2 and ≤ 34.9kg/m2)

          -  pre-diabetes

          -  aged between 30 - 65 years.

        Exclusion Criteria:

          -  diabetes mellitus

          -  gastroenterological diseases or major abdominal surgery (allowed i.e.:
             ---appendectomy, cholecystectomy)

          -  lactose intolerance and other digestive disorders

          -  cardiovascular disease, cancer, liver or kidney malfunction (determined based on ALAT
             and creatinine levels, respectively)

          -  disease with a life expectancy shorter than 5 years

          -  Use of antibiotics 3 months prior inclusion

          -  Use of probiotics or prebiotics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastricht University</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>5229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 6, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

